Abbott Laboratories (NYSE:ABT – Get Free Report) had its target price increased by investment analysts at BTIG Research from $131.00 to $134.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s price target would indicate a potential upside of 35.61% from the company’s current price.
A number of other brokerages have also recently weighed in on ABT. Jefferies Financial Group dropped their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Mizuho lowered their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein cut their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. JPMorgan Chase & Co. lowered their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.74.
Get Our Latest Stock Report on ABT
Abbott Laboratories Price Performance
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.
Insider Buying and Selling at Abbott Laboratories
In related news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.
Institutional Trading of Abbott Laboratories
Large investors have recently made changes to their positions in the company. Radnor Capital Management LLC lifted its stake in Abbott Laboratories by 4.3% in the second quarter. Radnor Capital Management LLC now owns 19,792 shares of the healthcare product maker’s stock worth $1,796,000 after acquiring an additional 807 shares during the last quarter. Activest Wealth Management increased its position in shares of Abbott Laboratories by 91.9% in the 2nd quarter. Activest Wealth Management now owns 856 shares of the healthcare product maker’s stock valued at $78,000 after purchasing an additional 410 shares during the last quarter. Brown Miller Wealth Management LLC raised its holdings in shares of Abbott Laboratories by 0.9% in the 2nd quarter. Brown Miller Wealth Management LLC now owns 41,809 shares of the healthcare product maker’s stock valued at $3,794,000 after purchasing an additional 370 shares in the last quarter. Simplify Asset Management Inc. lifted its position in shares of Abbott Laboratories by 32.5% during the 2nd quarter. Simplify Asset Management Inc. now owns 20,546 shares of the healthcare product maker’s stock worth $1,864,000 after purchasing an additional 5,040 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in Abbott Laboratories by 13.5% in the second quarter. Capital Advisors Ltd. LLC now owns 3,625 shares of the healthcare product maker’s stock valued at $329,000 after buying an additional 432 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, topping estimates, while revenue rose 13% year over year and sales growth was broad-based across medical devices, diagnostics, and nutrition. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, which suggests management is seeing better profitability trends than Wall Street expected. Abbott raises 2026 profit forecast on heart device strength
- Positive Sentiment: Investor sentiment improved because demand for Abbott’s heart devices and diagnostics appears to be strengthening, especially after management pointed to a better second-half outlook and continued momentum in those segments. Why Abbott Stock Jumped Today
- Neutral Sentiment: Abbott continues to trade well above its recent 50-day average, but it remains below its 200-day average, so the longer-term trend is still mixed despite the earnings-driven rebound.
- Negative Sentiment: Some headlines note that the stock had been under pressure earlier this year, and while the latest results helped, concerns about the broader trend and valuation are not fully gone. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
